Search

Your search keyword '"Qu, Yuan-yuan"' showing total 358 results
Start Over Author "Qu, Yuan-yuan"
358 results on '"Qu, Yuan-yuan"'

5. A phase 1/2 study to evaluate the efficacy and safety of HB0025 monotherapy for patients (pts) with advanced renal cell carcinoma (RCC).

Author

Qu, Yuan-Yuan, primary, Ye, Dingwei, additional, Bian, Xiaojie, additional, Han, Weiqing, additional, Liu, Kan, additional, Dai, Tao, additional, Sun, Yuping, additional, Bian, Jiasheng, additional, Dang, Qi, additional, Sun, Meili, additional, Wang, Zhen, additional, Zhang, Jian, additional, Zhou, Huan, additional, Gao, Zhenyuan, additional, Zhu, Xiangyang, additional, Yang, Yongmin, additional, Chen, Juan, additional, Yang, Yang, additional, Wang, Junning, additional, and Cai, Ye, additional

Published
2024
Full Text
View/download PDF

12. Table S3 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Author

Qu, Yuan-Yuan, primary, Zhang, Hai-Liang, primary, Guo, Hongqian, primary, Luo, Hong, primary, Zou, Qing, primary, Xing, Nianzeng, primary, Xia, Shujie, primary, Sun, Zhongquan, primary, Zhang, Xuepei, primary, He, Chaohong, primary, Cai, Jinling, primary, Zhang, Xiao, primary, Wang, Quanren, primary, and Ye, Ding-Wei, primary

Published
2023
Full Text
View/download PDF

13. Figure S1 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Author

Qu, Yuan-Yuan, primary, Zhang, Hai-Liang, primary, Guo, Hongqian, primary, Luo, Hong, primary, Zou, Qing, primary, Xing, Nianzeng, primary, Xia, Shujie, primary, Sun, Zhongquan, primary, Zhang, Xuepei, primary, He, Chaohong, primary, Cai, Jinling, primary, Zhang, Xiao, primary, Wang, Quanren, primary, and Ye, Ding-Wei, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Data from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Author

Qu, Yuan-Yuan, primary, Zhang, Hai-Liang, primary, Guo, Hongqian, primary, Luo, Hong, primary, Zou, Qing, primary, Xing, Nianzeng, primary, Xia, Shujie, primary, Sun, Zhongquan, primary, Zhang, Xuepei, primary, He, Chaohong, primary, Cai, Jinling, primary, Zhang, Xiao, primary, Wang, Quanren, primary, and Ye, Ding-Wei, primary

Published
2023
Full Text
View/download PDF

17. The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma

Author

Su, Jia-Qi, primary, Tian, Xi, additional, Xu, Wen-Hao, additional, Anwaier, Aihetaimujiang, additional, Ye, Shi-Qi, additional, Zhu, Shu-Xuan, additional, Wang, Yue, additional, Gu, Jun, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2022
Full Text
View/download PDF

22. Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Author

Qu, Yuan-Yuan, primary, Sun, Zhongquan, additional, Han, Weiqing, additional, Zou, Qing, additional, Xing, Nianzeng, additional, Luo, Hong, additional, Zhang, Xuepei, additional, He, Chaohong, additional, Bian, Xiao-Jie, additional, Cai, Jinling, additional, Chen, Chunxia, additional, Wang, Quanren, additional, and Ye, Ding-Wei, additional

Published
2022
Full Text
View/download PDF

24. High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma

Author

Wu, Jie, Wang, Yu-Chen, Xu, Wen-Hao, Luo, Wen-Jie, Wan, Fang-Ning, Zhang, Hai-Liang, Ye, Ding-Wei, Qu, Yuan-Yuan, and Zhu, Yi-Ping

Subjects
renal cell carcinoma, CD39, infiltrating immune cells, prognosis, TCGA, OncoTargets and Therapy, Original Research, immune checkpoint therapy
Abstract

Jie Wu,1,2,* Yu-Chen Wang,1,2,* Wen-Hao Xu,1,2,* Wen-Jie Luo,1,2 Fang-Ning Wan,1,2 Hai-Liang Zhang,1,2 Ding-Wei Ye,1,2 Yuan-Yuan Qu,1,2 Yi-Ping Zhu1,2 1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ding-Wei Ye; Yi-Ping ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, No. 270 Dong an Road, Shanghai 200032, People’s Republic of ChinaTel +86– 21– 64175590Fax +86– 21– 64438640Email fudanzhuyiping@163.com; dwyeli@yahoo.com.cnIntroduction: The cell-surface ectonucleotidase CD39 is a key molecule of the immunosuppressive adenosine pathway within the tumor microenvironment. However, the relationship between CD39 and clear cell renal cell carcinoma (ccRCC) is rarely reported and still remains unclear.Methods: CD39 expression was first analyzed using the Oncomine and the Tumor IMmune Estimation Resource (TIMER) databases, and then examined in ccRCC patients (n=367) who had undergone radical nephrectomy using immunohistochemistry (IHC) and real-time quantitative PCR analysis (qPCR). The prognosis value of CD39 in ccRCC was evaluated by Cox proportional hazards analysis. Functional and gene set enrichment analysis (GSEA) was performed using transcriptomic data of ccRCC from TCGA. Correlation analysis between CD39 and tumor-infiltrating lymphocytes (TILs) was performed using the TISIDB database. The impact of CD39 on immune checkpoint therapy (ICT) was evaluated by two public cohorts.Results: CD39 mRNA and protein expression was upregulated in tumor tissues from ccRCC patients and aberrant expression of CD39 was associated with advanced tumor stage and poor prognosis in ccRCC patients. EMT, IL-2/STAT5, inflammatory response, interferon gamma and KRAS hallmark gene sets were identified as CD39-related signaling pathway. The expression level of CD39 was significantly and positively correlated with high abundance of the regulatory TILs including NK cells, macrophages, Th cells and Treg cells. CD39 was correlated with expression of several immune checkpoints and higher CD39 expression was associated with better OS of ccRCC patients who received ICT.Conclusion: CD39 is a powerful prognostic marker of ccRCC patients. Increased tumor expression of CD39 mRNA is significantly correlated with infiltrating levels of TILs, and better efficacy of ICT to ccRCC. CD39 could be a novel therapeutic target for ccRCC.Keywords: renal cell carcinoma, CD39, prognosis, TCGA, infiltrating immune cells, immune checkpoint therapy

Published
2020

25. Additional file 2 of ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study

Author

Anwaier, Aihetaimujiang, Xu, Wen-Hao, Tian, Xi, Ding, Tao, Su, Jia-Qi, Wang, Yue, Qu, Yuan-Yuan, Zhang, Hai-Liang, and Ye, Ding-Wei

Abstract

Additional file 2. Supplementary Table 1. Distribution of prognostic risk factors in 57 renal eAML patient. Risk factors included: pT3 and pT4, presence of necrosis, mitotic count≥2; the presence of atypical mitoses; severe nuclear atypia, SMA negative, Ki-67≥10%. Low-risk group: including 0-1 risk factor, Intermediate-risk group: including 2-3 risk factors, High-risk group: including 4-7 risk factors. *p value less than 0.05 was considered as statistically significant and marked in bold.

Published
2022
Full Text
View/download PDF

26. Additional file 1 of ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study

Author

Anwaier, Aihetaimujiang, Xu, Wen-Hao, Tian, Xi, Ding, Tao, Su, Jia-Qi, Wang, Yue, Qu, Yuan-Yuan, Zhang, Hai-Liang, and Ye, Ding-Wei

Abstract

Additional file 1. Supplementary Figure 1. Correlation between clinical parameters and prognosis. Survival curves indicated the PFS (A) and OS (B) of total cohort. Patients with tumour size>7cm were significantly correlated with PFS (C) (HR=4.47, p=0.0061), but not significant in OS (D) (HR=4.61, p=0.053). Patients with pT3-pT4 stage were correlated with both shorter PFS (E) (HR=3.74, p=0.0044) and OS (F) (HR=10.27, p=0.0022). Patients with presence of atypical mitosis (G, H), presence of necrosis (I, J), severe nuclear atypia (K, L), and mitotic count >=2 (M, N) were significantly correlated with poor PFS (presence of atypical mitoses: HR=5.41, p=2: HR=7.56, p

Published
2022
Full Text
View/download PDF

31. Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response

Author

Tian, Xi, primary, Xu, Wen-Hao, additional, Xu, Fu-Jiang, additional, Li, Hui, additional, Anwaier, Aihetaimujiang, additional, Wang, Hong-Kai, additional, Wan, Fang-Ning, additional, Zhu, Yu-, additional, Cao, Da-Long, additional, Zhu, Yi-Ping, additional, Shi, Guo-Hai, additional, Qu, Yuan-Yuan, additional, Zhang, Hai-Liang, additional, and Ye, Ding-Wei, additional

Published
2022
Full Text
View/download PDF

34. Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma

Author

Wu, Xiaohui, primary, Tang, Haijia, additional, Xu, Wen-Hao, additional, Tang, Haidan, additional, Wei, Shiyin, additional, Anwaier, Aihetaimujiang, additional, Huang, Haineng, additional, Qu, Yuan-Yuan, additional, Zhang, Hailiang, additional, Zhao, Shuai, additional, Li, Hui, additional, Liu, Wangrui, additional, Chen, Hongjing, additional, Ding, Chen, additional, and Ye, Dingwei, additional

Published
2021
Full Text
View/download PDF

37. Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study

Author

Qu, Yuan-Yuan, primary, Zhang, Hai-Liang, additional, Guo, Hongqian, additional, Luo, Hong, additional, Zou, Qing, additional, Xing, Nianzeng, additional, Xia, Shujie, additional, Sun, Zhongquan, additional, Zhang, Xuepei, additional, He, Chaohong, additional, Cai, Jinling, additional, Zhang, Xiao, additional, Wang, Quanren, additional, and Ye, Ding-Wei, additional

Published
2021
Full Text
View/download PDF

42. Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

Author

Qu, Yuan-Yuan, primary, Zou, Qing, additional, Guo, Hongqian, additional, Xing, Nianzeng, additional, Sun, Zhongquan, additional, Han, Weiqing, additional, Luo, Hong, additional, Xia, Shujie, additional, Zhang, Xuepei, additional, He, Chaohong, additional, Zhang, Hailiang, additional, Cai, Jinling, additional, Zhang, Xiao, additional, Wang, Quanren, additional, and Ye, Dingwei, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results